Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Scholar Rock auf dem Biopharma-Gipfel der Citigroup: FDA-Entscheidung rückt näher (Investing.com DE) +++ SCHOLAR ROCK Aktie +3,04%

SCHOLAR ROCK Aktie

 >SCHOLAR ROCK Aktienkurs 
48.565 EUR    (TradegateBSX)
Ask: 48.74 EUR / 400 Stück
Bid: 48.39 EUR / 400 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
SCHOLAR ROCK Aktie über LYNX handeln
>SCHOLAR ROCK Performance
1 Woche: -4,3%
1 Monat: +1,4%
3 Monate: +18,9%
6 Monate: +28,4%
1 Jahr: +76,7%
laufendes Jahr: +18,7%
>SCHOLAR ROCK Aktie
Name:  SCHOLAR ROCK HLDG DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US80706P1030 / A2JMQW
Symbol/ Ticker:  2QK (Frankfurt) / SRRK (NASDAQ)
Kürzel:  FRA:2QK, ETR:2QK, 2QK:GR, NASDAQ:SRRK
Index:  -
Profil:  Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare n..
>Volltext..
Marktkapitalisierung:  5802.82 Mio. EUR
Unternehmenswert:  5554.59 Mio. EUR
Umsatz:  -
EBITDA:  -348.67 Mio. EUR
Nettogewinn:  -351.86 Mio. EUR
Gewinn je Aktie:  -2.97 EUR
Schulden:  175.53 Mio. EUR
Liquide Mittel:  376.41 Mio. EUR
Operativer Cashflow:  -255.62 Mio. EUR
Bargeldquote:  6.81
Umsatzwachstum:  -
Gewinnwachstum:  -29.43%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  SCHOLAR ROCK
Letzte Datenerhebung:  10.09.26
>SCHOLAR ROCK Kennzahlen
Aktien/ Unternehmen:
Aktien: 121.79 Mio. St.
Frei handelbar: 81.53%
Rückkaufquote: -5.23%
Mitarbeiter: 289
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 11.33%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 26.51
PEG-Ratio: -1.13
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -94.63%
Eigenkaprendite: -167.77%
>SCHOLAR ROCK Peer Group
Gesundheit, Neurologische Erkrankungen/ Schlaganfälle
 
10.09.26 - 16:31
Scholar Rock auf dem Biopharma-Gipfel der Citigroup: FDA-Entscheidung rückt näher (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
09.09.26 - 15:06
Scholar Rock auf der Cantor Global Healthcare Conference: Zulassung für Apitegromab rückt näher (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
14.08.26 - 22:21
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
 
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate of 14,889 shares of common stock and inducement restricted stock units, covering an aggregate of 37,058 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing ...
13.08.26 - 15:48
Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript (Fool)
 
Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment....
12.08.26 - 20:48
Scholar Rock auf Canaccord-Wachstumskonferenz: Probleme bei Auftragsfertiger verändern Zulassungspfad für Apitegromab (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.08.26 - 18:18
Scholar Rock targets September 30 PDUFA decision with 2 independent fill/finish paths (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.07.26 - 01:15
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm (PR Newswire)
 
NEW YORK, July 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK) breached their fiduciary duties to shareholders. The investigation concerns potential......
16.07.26 - 14:09
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
 
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call. An archived replay of the webcast will be available on the Company's website for approximately 90 days. About Scholar Rock Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a globa...
07.07.26 - 01:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Scholar Rock Holding im Wert von 164068 USD (Insiderkauf)
 
Reed, Joshua - Aufsichtsrat - Tag der Transaktion: 2026-07-01...
07.07.26 - 01:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Scholar Rock Holding im Wert von 164490 USD (Insiderkauf)
 
Flier, Jeffrey S. - Aufsichtsrat - Tag der Transaktion: 2026-07-01...
07.07.26 - 01:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Scholar Rock Holding im Wert von 293405 USD (Insiderkauf)
 
Peng, Katie - Aufsichtsrat - Tag der Transaktion: 2026-07-01...
07.07.26 - 01:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Scholar Rock Holding im Wert von 137058 USD (Insiderkauf)
 
Gilman, Michael - Aufsichtsrat - Tag der Transaktion: 2026-07-01...
07.07.26 - 01:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Scholar Rock Holding im Wert von 164064 USD (Insiderkauf)
 
Burow, Kristina - Aufsichtsrat - Tag der Transaktion: 2026-07-01...
15.06.26 - 15:48
Moon Rabbit Expands Client Roster and Senior Leadership, Garners More Industry Recognition (PR Newswire)
 
LEO Pharma, Scholar Rock and American Express among recent client wins; named Agency of the Year at 37th annual Manny Awards NEW YORK, June 15, 2026 /PRNewswire-PRWeb/ -- Moon Rabbit, an award-winning independent advertising and media agency, today announced new business wins, leadership......
12.06.26 - 22:18
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
 
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 134,345 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 50,936 shares of common stock and inducement restricted stock units, covering an aggregate of 83,409 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing...
15.05.26 - 22:18
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
 
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 12,061 shares of common stock and inducement restricted stock units, covering an aggregate of 26,420 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rul...
13.05.26 - 19:54
Scholar Rock: Aktie steigt trotz verfehlter Gewinnprognose für Q1 2026 (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
08.05.26 - 17:36
Scholar Rock (SRRK) Q1 2026 Earnings Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
07.05.26 - 21:06
Scholar Rock anticipates apitegromab approval by September 30 as FDA accepts SMA BLA with two fill-finish sites (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.05.26 - 16:54
Earnings Call zu Q1 2026: Scholar Rock verfehlt Gewinnprognose, zeigt sich aber finanziell robust (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Überalterung ist vor allem ein Problem der leitenden Gremien. - Dr. Gerhard Kocher
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!